Alpha Omega Wealth Management’s Ionis Pharmaceuticals IONS Stock Holding History

Alpha Omega Wealth Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-149	Closed	-$10K	–	382
2019 Q2	$10K	Hold	149	–	–	﹤0.01%	439
2019 Q1	$12K	Buy	+149	New	+$9.61K	0.01%	408

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Alpha Omega Wealth Management's IONS Position: Q3 2019 in Review

Alpha Omega Wealth Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2019, closing a stake of 149 shares — an estimated $10K sold.

Alpha Omega Wealth Management first reported a position in IONS in Q1 2019 and held it in 2 quarters. The position peaked at $12K in Q1 2019. 369 funds tracked by Wall St. Rank hold IONS as of Q3 2019.

Alpha Omega Wealth Management reported no remaining Ionis Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Alpha Omega Wealth Management sold 149 Ionis Pharmaceuticals shares in Q3 2019, an estimated $10K.
Alpha Omega Wealth Management first reported a position in Ionis Pharmaceuticals in Q1 2019 and held it in 2 quarters.
Alpha Omega Wealth Management's Ionis Pharmaceuticals position peaked at $12K in Q1 2019.
369 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2019.

Based on Alpha Omega Wealth Management's 13F filing for Q3 2019, filed 12 Nov 2019.